Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Parallel Group Treatment, Phase 2A, Double-blind, 3-arm Study to Investigate Safety and Efficacy of ABX-101 Compared With Placebo in Male and Female Participants, Aged 18 to 50 Years, With Moderate-to-severe Traumatic Brain Injury

NCT06096415 is registered in ClinicalTrials.gov with Abalonex, LLC as lead sponsor.

NCT NCT06096415
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06096415 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Parallel Group Treatment, Phase 2A, Double-blind, 3-arm Study to Investigate Safety and Efficacy of ABX-101 Compared With Placebo in Male and Female Participants, Aged 18 to 50 Years, With Moderate-to-severe Traumatic Brain Injury
Lead sponsor
Abalonex, LLC
Phase
Phase 2
Overall status
Unknown status
Start date
December 31, 2023
Completion date
May 31, 2024
Enrollment
45 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cerebral edema, traumatic brain injury